HOME > TOP STORIES

TOP STORIES

BUSINESS Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool

May 21, 2025
REGULATORY Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More

May 20, 2025
ORGANIZATION PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action

May 19, 2025
BUSINESS Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO

May 16, 2025
REGULATORY Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval

May 15, 2025
REGULATORY Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule

May 15, 2025
REGULATORY Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA

May 15, 2025
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026

May 15, 2025
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme

May 15, 2025
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act

May 15, 2025
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing

May 14, 2025
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds

May 14, 2025
BUSINESS J&J Taps Chris Rieger to Lead Japan Pharma Business

May 13, 2025
REGULATORY MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary

May 12, 2025
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market

May 9, 2025
BUSINESS Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers

May 9, 2025
BUSINESS Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz

May 8, 2025
COMMENTARY New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey

May 8, 2025
REGULATORY MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program

May 7, 2025
BUSINESS Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People

May 1, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…